Steris (DE:2TG)
NYSE:2TG
2TG Stock Chart & Stats
€228.00
€4.00(2.00%)
At close: 4:00 PM EST
€228.00
€4.00(2.00%)
Day’s Range― - ―
52-Week Range€170.40 - €236.00
Previous CloseN/A
Volume61.00
Average Volume (3M)15.00
Market Cap
€17.67B
Enterprise Value€22.37B
Total Cash (Recent Filing)€439.60M
Total Debt (Recent Filing)€2.09B
Price to Earnings (P/E)26.6
Beta0.26
Next Earnings
Aug 10, 2026EPS Estimate
2.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.95
Shares Outstanding97,602,486
10 Day Avg. Volume5
30 Day Avg. Volume15
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)3.02
Price to Sales (P/S)3.66
P/FCF Ratio22.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€244.99Price Target Upside7.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)9.6
Revenue Forecast (FY)€5.48B
Bulls Say, Bears Say
Bulls Say
Earnings StabilityEarnings matched expectations and management reaffirmed the earnings outlook, supporting confidence in the company's profit execution.
Organic Growth OutlookManagement reiterated organic growth guidance, suggesting continued underlying sales momentum beyond acquisition effects.
Revenue PerformanceManagement reiterated revenue guidance after reporting revenue modestly above consensus, signaling resilient demand across core businesses.
Bears Say
Margin DeteriorationGross and operating margins declined below expectations, indicating margin pressure that may weigh on overall profitability.
Sector Demand WeaknessOrganic revenue growth slowed as sales weakened in Healthcare and Life Sciences, raising concerns about demand in key end markets.
Tariff-driven Cost PressureManagement increased the estimated tariff-related expense, pointing to higher input costs that could compress profit margins.
Steris News
2TG FAQ
What was Steris’s price range in the past 12 months?
Steris lowest stock price was €170.40 and its highest was €236.00 in the past 12 months.
What is Steris’s market cap?
Steris’s market cap is €17.67B.
When is Steris’s upcoming earnings report date?
Steris’s upcoming earnings report date is Aug 10, 2026 which is in 65 days.
How were Steris’s earnings last quarter?
Steris released its earnings results on May 11, 2026. The company reported €2.427 earnings per share for the quarter, missing the consensus estimate of €2.444 by -€0.016.
Is Steris overvalued?
According to Wall Street analysts Steris’s price is currently Undervalued.
Does Steris pay dividends?
Steris does not currently pay dividends.
What is Steris’s EPS estimate?
Steris’s EPS estimate is 2.15.
How many shares outstanding does Steris have?
Steris has 97,602,486 shares outstanding.
What happened to Steris’s price movement after its last earnings report?
Steris reported an EPS of €2.427 in its last earnings report, missing expectations of €2.444. Following the earnings report the stock price went up 4.842%.
Which hedge fund is a major shareholder of Steris?
Currently, no hedge funds are holding shares in DE:2TG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Steris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€244.99 (7.45% Upside)
€244.99 (7.45% Upside)
Blogger Sentiment
Bullish
DE:2TG Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €900.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.45%
12-Months-Change
Fundamentals
Return on Equity
11.05%
Trailing 12-Months
Asset Growth
5.82%
Trailing 12-Months
Company Description
Steris
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
2TG Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive financial and operational picture: STERIS delivered a record fiscal 2026 with double-digit adjusted EPS growth, exceptional free cash flow (~$983M), stronger leverage (gross debt/EBITDA ~1.2x), and multiple segment milestones (Healthcare, AST, Life Sciences). Management provided constructive FY2027 guidance (7–8% revenue growth, EPS up ~9–11%, modest margin expansion) while continuing shareholder returns (dividend increase, $1B buyback authorization) and strategic investments (manufacturing consolidation, tuck-in M&A, AI for service). Offsetting these positives are tangible near-term headwinds: tariff costs (~$60–65M annual spend with no refunds assumed), higher effective tax rates due to withholding and geographic mix, Q4 margin compression, AST service softness and inventory-led demand variability, and a forecasted reduction in free cash flow for FY2027. Overall, the highlights — record growth, strong cash generation, prudent capital allocation, and constructive guidance — outweigh the lowlights, which are manageable but notable operational and tax/tariff risks.View all DE:2TG earnings summaries2TG Revenue Breakdown
73.00% U.S.
25.39% Other locations
1.61% Ireland
2TG Stock 12 Month Forecast
Average Price Target
€244.99
▲(7.45% Upside)
Technical Analysis
Dexcom
―
Insulet
―
Koninklijke Philips
―
Smith & Nephew Snats
―
Zimmer Biomet Holdings
―
Options Prices
Currently, No data available
---